Sign In
Buy SITC
$4.88
-0.0500 (-1.01%)
At Close: Jun 03, 2026
Fisher Asset Management LLC Sells 182,310 Shares of Site Centers Corp. $SITC
04:12am, Saturday, 06'th Dec 2025
Fisher Asset Management LLC lessened its holdings in shares of Site Centers Corp. (NYSE: SITC) by 62.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 110,813
SITE Centers Provides Update on Disposition Activity and Go Forward Plan
04:06pm, Thursday, 04'th Dec 2025
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Provides Update on Disposition Activity and Go Forward Plan.
SITE Centers Announces Special Common Stock Distribution and Debt Payoff
04:05pm, Thursday, 04'th Dec 2025
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Special Common Stock Distribution and Debt Payoff.
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 14,531 Shares of Site Centers Corp. $SITC
04:00am, Saturday, 29'th Nov 2025
Commonwealth of Pennsylvania Public School Empls Retrmt SYS reduced its position in Site Centers Corp. (NYSE: SITC) by 54.5% during the second quarter, according to its most recent filing with the Sec
SITE Centers Announces Sales of Four Properties
04:47pm, Friday, 21'st Nov 2025
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sales of Four Properties.
SITE Centers Announces Sale of Paradise Village Gateway
06:29pm, Thursday, 20'th Nov 2025
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Paradise Village Gateway.
REIT Replay: REIT Indexes Outperform Broader Markets During 1st Week Of November
07:41am, Tuesday, 11'th Nov 2025
Indexes tracking real estate investment trust stocks outperformed the broader stock market indexes during the first week of November. The Dow Jones Equity All REIT closed the recent week up 1.40%, whi
Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025
11:30am, Friday, 07'th Nov 2025
HONG KONG , Nov. 7, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) published the preclinical research data for its novel antagonistic monoclonal antibody targeting IL-1RAP, AK135, at the 40th Annual
40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB)
Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and b
SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety
NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapi
Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vac
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
09:00am, Friday, 07'th Nov 2025
– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –
